Related Experiment Videos
Randomized, double-blind study of levamisole in recurrent aphthous stomatitis
Journal of Oral Pathology
|January 1, 1978
Summary
Levamisole did not effectively treat recurrent aphthous stomatitis (RAS) in a randomized trial. The drug showed no significant difference compared to placebo in reducing ulcer incidence or severity.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Recurrent aphthous stomatitis (RAS) is a common oral condition causing significant discomfort.
- Current treatments for RAS have varying efficacy and potential side effects.
Purpose of the Study:
- To evaluate the safety and efficacy of levamisole for treating recurrent aphthous stomatitis (RAS).
Main Methods:
- A randomized, double-blind, placebo-controlled study.
- Thirty patients with a history of frequent RAS episodes were enrolled.
- Participants received 150 mg of levamisole or placebo daily for 3 days at the onset of symptoms, repeated as needed.
Main Results:
- Data from 24 patients were analyzed.
- Levamisole group: 6 slight improvement, 5 unchanged.
- Placebo group: 1 marked improvement, 4 slight improvement, 6 unchanged, 2 deteriorated.
- No statistically significant difference in outcomes between levamisole and placebo groups.
Conclusions:
- Levamisole, under the study protocol, demonstrated no significant effect on the incidence or severity of aphthous ulcers.
- Further research may be needed to explore alternative treatment strategies for RAS.